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Abstract
Background Increasingly, patients are expected to influ-
ence decisions previously reserved for regulatory agencies,
pharmaceutical companies, and healthcare professionals.
Individual patients have previously represented their
patient population when rare, serious adverse events (AEs)
were weighed as part of a benefit-risk assessment. How-
ever, the degree of heterogeneity of the patient population
is critical for how accurately they can be represented by
individuals.
Objectives This study aims to explore patients’ risk per-
ception of rare, serious adverse effects of medicines with
regard to blood glucose-lowering antidiabetics used by the
individual patient.
Methods Semi-structured interviews were conducted with
18 patients with diabetes with self-perceived serious, but
not necessarily rare, AEs (e.g. stroke or valve or bypass
surgery). The interviews explored the patients’ history of
disease, perceptions of the terms rare and serious, and
overall levels of risk aversion. A thematic analysis of the
interviews, including a consensus discussion, was carried
out.
Results Interestingly, respondents rarely made a clear
distinction between medicines-induced AEs and compli-
cations related to disease progression. Concerns regarding
AEs were apparently diverse but were systematically
related to the personal experiences of the respondents.
Respondents routinely ignored information about possible
rare, serious AEs, unless it could be related to personal
experience. In the absence of experience, concerns were
focused on common and less serious AEs, thus disregard-
ing rare and more serious events.
Conclusion The study suggests that experience of AEs,
related to either medicines or disease, constitutes an
important factor of patient risk perception. We therefore
propose that serious adverse experiences should be added
to the traditional panel of socioeconomic factors that are
accounted for when patients are invited to give input on
regulatory decisions.
Key Points
The interviewed patients primarily described
experienced events that had either obstructed
everyday life or were particularly frightening as
serious, and these were the focus of future concern.
Patients who seemed alike were not concerned with
the same type of adverse events (AEs), suggesting
attitudes towards AEs of diverse patient groups are
not easily represented.
The study suggests that the personal experience of
patients with AEs should be considered when
authorities seek to include patients in developing
regulatory decisions.
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1 Introduction
A favorable benefit-risk assessment (BRA) is pivotal to the
approval of a new pharmaceutical product.1 In pursuit of an
‘explicit, consistent, transparent, and aggregate’ [1] foun-
dation for BRAs, considerable efforts have been dedicated
to the development of numerous qualitative and quantita-
tive methodologies [2–6]. To improve the tools of decision
making, companies and patient organizations have recently
encouraged the inclusion of patients in the decision making
of market approval processes of medicines authorities
[7–11]. Patients can be involved in different stages of
regulatory decision making, including weighing the bene-
fits of a medicine against risks to assess whether a final
market approval should be granted. Patients are considered
important in this process, first because they are the ones to
receive the medicine and live with the consequences of the
decisions taken and, second, because their views appear to
be lacking in regulatory decision-making processes, as lay
people’s risk-assessment of medicines have been found to
differ from those of experts [12–14]. Hence, recent studies
conducted in the medical field of risk perception show that
patients estimate benefits higher and risks lower than reg-
ulators and healthcare professionals, regardless of the
intervention, clinical context, or patient population
involved [15].
A particular difficulty in granting marketing authoriza-
tions of pharmaceutical products is determining the impact
of rare, serious adverse events on decisions. One difficulty
relates to the predictive power of clinical trials, as even
sample sizes of 4000 participants are too small to detect
rare events [16–18]. Hence, uncertainties about rare
adverse events (AE) exist at the time of approval. The other
challenge is defined by the perception of the seriousness of
an event should it occur. Studies have shown that experts
and patients weigh AEs differently. Patients weigh impact
on everyday life higher compared with experts [19], and
highest among adverse drug reactions [20]. The difficulty is
further accentuated in case of the combination of rare and
serious events because the basis for weighing is often
inadequate.
Risk perception is the subjective judgment that people
make about the characteristics and severity of a risk. This
definition of risk perception proposed by Starr in 1969 is
still widely used. Gierlach et al. narrow the definition and
describe a subjective judgment about the felt likelihood of
encountering hazards when objective information is mini-
mal as an inherently psychological construct [21]. Factors
that affect the psychological construct of risk perception
are the matter of the theoretical framework of cognitive
biases. Described as predictable deviations from rationality
[22], descriptions of cognitive biases aim at, and often
succeed in, characterizing factors affecting risk perception.
A variety of biases have been proposed within the frame-
work and several are relevant to risk perception regarding
rare, serious AEs: events present in the memory (available)
are assessed as having a larger perceived risk of occurring
(Availability bias) [23, 24]; the tendency to avoid choices
with unknown probabilities (Ambiguity effect) [25];
neglect of background incidence and focus on individual
cases (Base rate neglect) [26]; the tendency to stick to an
established belief in the face of new evidence (Belief
revision) [27]; the tendency to prefer immediate payoffs as
opposed to later payoffs (Current moment bias) [28]; and
the tendency to focus on impact and disregard probability
when making decisions under uncertainty (Probability
neglect) [29].
The cognitive biases presented above show that the
perceived risk can be very different from an objective risk,
supported by Klein and Stefanek [30]. When experience
and information are abundant, this difference reduced.
Considerations regarding rare, serious AEs are therefore
particularly vulnerable to cognitive biases. Furthermore,
little is known about how patients consider the risk of
future rare, serious AEs in relation to treatment for one or
more chronic diseases that have not progressed to an
invalidating stage, such as diabetes, and cardiovascular and
pulmonary disease.
Patients affected by chronic disease have been described
as heterogeneous (diabetes [31], chronic obstructive pul-
monary disease [COPD] [32], rheumatoid arthritis [33],
and asthma [34]). Such heterogeneity is a challenge for
patient involvement since representability is greatly influ-
enced by intervariability. Patients have previously been
involved in, and subsequently impacted, regulatory deci-
sions [35–37], a canonical example being involvement of
patients severely affected by relapsing late-stage multiple
sclerosis contributing to the BRA of the medicine
Tysabri. No assessment of the heterogeneity of the
involved patients could be found but it stands as an
example of patient homogeneity that is probably not
reflected in the large groups of chronic diseases. Knowl-
edge about how patients perceive rare, serious risks is
crucial in order to qualify patient input in future regulatory
decisions for the treatment of diseases that are among the
most prevalent globally.
The aim of the study was to explore patients’ risk per-
ception of possible rare, serious adverse effects of
1 In this study, pharmaceutical products will be termed medicines
according to European convention; however, the term drug is
standard in the US. The difference in terminology is apparent in the
names of the respective regulatory agencies: US FDA versus
European Medicines Agency. The term drug encompasses substances
that exert an effect in the organism, whereas the term medicines is
given as the subset of drugs used to treat or prevent a disease or an
unwanted condition.
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medicines with regard to blood glucose-lowering antidia-
betics used by the individual patient.
2 Methods
To explore patients’ risk perception of rare, serious adverse
effects of medicines with regard to blood glucose-lowering
antidiabetics used by the individual patient, a semi-struc-
tured interview study was conducted. This method was
chosen to explore the often very personal, even intimate
perceptions, attitudes and experiences that patients con-
sider important in relation to AEs [38].
Diabetes was found to be suitable to study rare, serious
AEs in a heterogeneous patient population. A long time-
frame from diagnosis to death, as well as multiple treat-
ment options, could potentially result in multifaceted
perceptions of risks and benefits with respect to treatment
and disease progression [39]. In addition, antidiabetic
treatment has been subject to long-standing regulatory
attention, with specific regard to the occurrence of rare,
severe cardiovascular events [40, 41].
2.1 Interview Guide
The purpose of the interview guide was to expose the
reasoning behind the concern, if present, for future rare,
serious AEs. The themes and questions of the interview
guide were based on a literature review of risk perception
[42–45] and burden of diabetes [39, 46–49]. These reviews
suggested that risk should be expected to be perceived
differently between individuals. The interview guide
accommodated this by posing open questions, with the
opportunity for the researcher to follow-up.
The first part of the interview guide explored patients’
medical histories, with a focus on their positive and neg-
ative experiences with diabetes medicines as previous
experiences have been described to be important for indi-
vidual risk assessments [23].
The second part focused on how participants understood
and used the terms rare and serious. Participants were
asked to describe the meaning of the terms in the context of
AEs and, if possible, to give examples of both rare and
serious events.
The third part of the interview guide was designed to
let respondents express how prevalence and seriousness
contributed to the perceived risk of specific AEs. To
obtain this, patients were presented with a slightly mod-
ified table of AEs (AE table) from the relevant glucose-
lowering pharmaceutical product that each individual
patient had been treated with. The participant was asked
to think out loud while reading through the entire table.
Information about manufacturer, brand name and dosing
are not part of the results, analysis, and discussion. The
table was taken from the Summary of Product Charac-
teristics (SmPC) on the website of the European
Medicines Agency, and supplemented with numerical
prevalence intervals from common to very rare
(1:10–1:10000).
The initial intention of presenting participants with the
AE table was for them to rank the AEs in the AE table from
most to least dreaded. The first three respondents were
unable to provide such ranking of AEs based on the AE
table; however, instead, they gave rich details related to the
listed AEs they had themselves experienced. The interview
guide was therefore changed to investigate which AEs on
the list were given attention and why.
2.2 Sample
Inclusion criteria were diagnosed with type 2 diabetes,
undergoing treatment with a blood glucose-lowering
pharmaceutical, and experience of a cardiovascular,
nephrotic, or peripheral nerve complication that patients
themselves judged as serious. This strategy enabled the
recruitment of respondents who could give anecdotal rather
than hypothetical responses. Recruitment of patients hav-
ing experienced a rare event with a confirmed relation to an
antidiabetic was considered not feasible.
Participants were recruited from all parts of Denmark
between September 2015 and May 2016. As the recruit-
ment of participants for the study proved difficult, partic-
ipants were recruited from several recruitment channels:
the website of the Danish Diabetics Association (DDA),
through chairpersons of the 92 local chapters of the DDA,
Danish diabetes Facebook groups, and relevant staff of
nursing units of 130 municipal health centers, along with
diabetic/metabolic/endocrinological/cardiovascular clinics
of 13 public hospitals across the country.
2.3 Data Collection
Each respondent was given information about his or her
participation, both orally and in writing. Participants signed
an informed consent form prior to the start of each inter-
view. The interviews were held in the patients’ homes.
Parts 1, 2, and 3 of the interview guide were addressed
in this order in the interview setting. During each inter-
view, the researcher gave summaries and brief interpreta-
tions when possible, thereby allowing respondents to verify
the initial interpretations of the researcher. This incorpo-
rated the initial phases of the analysis in the interview, and
not only simplifies these early analytical steps but also
places the analysis on firmer ground, as described by both
Morse et al. and Kvale and Brinkmann [50, 51]. As most
respondents had difficulties explaining their perceptions,
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reformulations of questions and extensive probing were
carried out [51, 52].
A debriefing routine was completed after each inter-
view, with the first author conducting all interviews. The
interviews were audio recorded and transcribed verbatim.
No financial incentives were offered or transacted.
2.4 Data Analysis
The analytical approach used was based on the six phases
of thematic analysis described by Braun and Clarke [53].
The analytical process enabled the authors to explore risk
perception regarding rare, serious AEs in patients despite
varying degrees of preconceptions. The first six interviews
were analyzed in parallel by the first and second authors.
After initial coding and theme identification [54], the
researchers aligned inductive outcomes through discussion.
The established themes were presented, discussed, merged,
and adjusted. The remaining 12 interviews were deduc-
tively analyzed by the first author and added to the ana-
lytical corpus. The third author independently evaluated
the coherence between the previously established themes
and the analytical output after reading all interviews.
The analytical process gave rise to three themes. The
first two showed, as planned, how respondents defined rare
AEs and serious AEs, respectively, whereas the last theme
inductively emerged from the interviews. It demonstrated
how respondents handled rare versus serious AEs based on
prior experience.
Qualitative studies aim to achieve saturation, the
threshold where further interviews reveal no new signifi-
cant aspects of the research topic. The last three respon-
dents did not present considerations that had not been
previously expressed by other participants and it was
concluded that the most prevalent themes had been cap-
tured. However, it should be noted that one of the last three
respondents presented a unique example of how to consider
rare AEs, and this parameter is not claimed as saturated
(see Fig. 2, right).
3 Results
3.1 Participant Demographics
Eighteen interviews were included in the study. The
interviews took between 30 and 130 min, with an average
of 70 min.
Participants were 55–83 years of age, with a median age
of 72 years, and had been diagnosed with type 2 diabetes
between 1 and 28 years prior to the study, with a median of
16 years. Thirteen of the 18 respondents were male and all
were Caucasian. The following channels of recruitment
were employed (successful contacts in brackets). Chair-
persons of the 92 local chapters of the DDA were per-
sonally contacted via mail (n = 4), and personal indirect
contact (n = 1) and contact directly via Danish diabetes
Facebook groups (n = 1) was employed. Phone calls were
placed with relevant staff, often the Nursing Head of Unit,
to increase attention to leaflets sent to the 130 Municipal
Health Centers (n = 5) and to the diabetic/metabolic/en-
docrinological/cardiovascular clinics of the public hospi-
tals across the country (n = 9).
Reported experienced AEs that were considered serious
included impaired vision, kidney failure, neuropathy, sex-
ual dysfunction, and cardiovascular disease. See Table 1
for respondent composition in terms of sex, age, duration
of diabetes mellitus type 2, medication, and the adverse
experiences mentioned during the interviews.
3.2 Characterization of Serious Adverse Events
(AEs)
When respondents described the term serious, they gave
examples of events related to both disease progression and
medical products. Hence, respondents consistently referred
to personal experience when describing the term serious
(see Fig. 1, left). In other words, when reflecting about
seriousness, only a few respondents recalled information
about potential serious AEs related to medicines or disease
progression that was not related to personal experience (see
Fig. 1, right).
Participants often did not distinguish between medicines
and disease progression as the cause for serious AEs.
Interviewer: ‘‘Regarding side effects, what would be
serious to you?’’
Patient 02: ‘‘The eyes. If I couldn’t see any more, that
would be terrifying. And the eyes are a typical side
effect.’’
In this example, Patient 02 seems to be mistaking the
term side effects for the term complications. Other exam-
ples include Patients 04–09, 16 and 17 who initially, during
the interview, specifically stated that they had not experi-
enced any medicines-related AEs, but later in the respec-
tive interviews respondents described AEs as linked to the
ingestion of a medicine. Two participants specifically sta-
ted that they did not know whether experienced AEs were
due to medication or due to disease.
Most respondents’ characterization of events included
two aspects: lasting negative influence on everyday life
(e.g. sexual dysfunction, immobilization, heart failure) and/
or an alarming event (anaphylactic reaction, myocardial
infarction, amputation). Furthermore, respondents often
related ongoing events to their description of the term
serious (see Fig. 1, lower right). However, particularly
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alarming events stayed with the respondents and were a
part of their risk perception.
Divergent views of the term serious were observed.
Patients reported experiences as diverse as coughing, sev-
ere muscle pain, and thrombotic events as both serious and
not serious.
Patient 08: ‘‘In the spring of 2016 I experienced two
thrombotic events, one in the heart and one in the
brain. Nothing serious – not at all. However, I was
rushed to the hospital. I highly doubt if that was
necessary.’’
The diversity illustrates that events were perceived as
either negligible or serious depending on the individual and
the conditions surrounding the event.
Events were considered serious when they were asso-
ciated with adverse impacts on quality of life. An example
was Patient 04, who was treated for chronic heart failure,
myocardial infarction, and a perforated colon. However,
when describing the term serious, he described three con-
ditions with little resemblance to these previous life-
threatening experiences: sexual dysfunction, neurological
changes (fearing amputation), and cataracts/decreasing
visual function (fearing blindness). The neurological con-
cern related to an experience in 1989 where, as a patient at
a hospital, the amputation of the foot of another patient had
made a lasting impression. The experience of both catar-
acts and retinal detachment had likewise made the
respondent concerned for loss of vision.
3.3 Characterization of Rare AEs
Respondents often struggled when asked to describe the
term ‘rare’ and often left the term unexplained, either
because it was difficult for them to relate to the term ‘rare’
or because they did not find rare events to be relevant when
considering personal risk. In particular, it was difficult to
express if they had no previous experience considered as
rare (see Fig. 2, left).
Four respondents considered rare events relevant.
Among these, three different subjective definitions of the
term emerged. More are speculated to exist. According to
Table 1 Overview of respondent demographics
IDa Sex Age,
years
DM2b Treatmentc Health issues experienced, and self-reported during interviews
Pt01 M 68 21 A, B, C Cardiac valve replacement, cardiac output, gastroparesis, vision, kidney failure
Pt02 M 73 16 A, C1, C3 Cardiac valve replacement, double coronary bypass surgery, familial hypercholesterolemia
Pt03 F 72 1 A Pacemaker, cardiac output, thrombosis (site unknown), vision, shortness of breath, cough, bilateral
hip–single knee joint replacement, arthritis
Pt04 M 74 20 A, B, C2 Myocardial infarction, heart failure, sexual dysfunction
Pt05 M 71 24 A, B, C, E Hypertension, arthritis, neuropathy
Pt06 M 55 8 A High blood pressure, acute cerebral thrombosis, nephropathy, gout, kidney function
Pt07 M 66 4 A, B 29 acute myocardial infarction, automated implantable cardioverter defibrillator, cardiac output,
vision, atherosclerosis of lower extremities
Pt08 M 65 15 A, B 29 acute myocardial infarction, triple coronary bypass surgery, cardiac valve replacement, hearing,
sleep apnea
Pt09 M 74 16 A, C1, C3 Distorted nerve signaling from lower extremities, vision
Pt10 M 83 20 A, B, C2,
D
Quadruple coronary bypass surgery, pacemaker, shortness of breath
Pt11 F 72 6 A Cardiac output, two cardioversions, cough, vision
Pt12 M 70 16 A, C No perceived additional health issues
Pt13 M 75 8 A Myocardial infarction, hypertension, hypercholesterolemia
Pt14 M 80 20 A, B, C Triple coronary bypass surgery
Pt15 M 76 27 A, C2 Nephropathy, hypertension, hypercholesterolemia
Pt16 F 78 10 A, E No perceived additional health issues
Pt17 F 71 28 A Acute cerebral thrombosis, acute medicine-induced allergic reaction, hypertension
Pt18 F 55 16 C2 Pacemaker, respiratory function, thoracic pain, left-sided heart failure
M male, F female, A oral metformin, B glucagon-like peptide-1 agonist, C insulin (1: fast; 2: intermediate; 3: prolonged), D Selective sodium
glucose co-transporter-2 (SGLT-2) inhibitor, Pt patient
a Respondent identifier
b Years since diagnosis of diabetes mellitus type 2
c Blood glucose-lowering treatment reported to have been received since diagnosis
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these respondents, ‘rare’ could refer to (1) a regulatory
construct, (2) events in an individual, or simply (3) events
experienced once (see description below and Fig. 2, lower
right).
First, when Patient 10 was asked if ‘rare’ was a
threshold determined by authorities, i.e. related to the
prevalence of an AE in a population of patients, the
respondent explained that he had not paid attention to
prevalence, rare or common, to the AE of shortness of
breath, which he experienced chronically. However, he
understood from the product information leaflet that the
specific event was indeed rare.
Patient 10: They [the authorities] are the ones that
establish that something is rare. They say this
[chronic shortness of breath] can happen to 1 in
10,000 patients, but then I say well that one, that’s
me. I’m the 1 in 10,000.’’
Second, ‘rare’ was described in relation to the ratio
between experienced and potential events experienced by
an individual. This was based on the following experience:
over 16 years with diabetes, with between three to four
blood glucose measurements per day, a participant had
experienced hypoglycemic events only twice.
Patient 09: ‘‘Rare in my case – that must be some-
thing like low blood sugar.’’
Third, one patient only took into account events that she
had experienced once when describing what could be
viewed as rare. After an event of ‘three small blood clots in
the neck’, the respondent was administered antihyperten-
sive treatment, resulting in a generalized anaphylactic
reaction.
Fig. 1 Differences and similarities: how patients characterized
serious. The thickness of the line indicates the frequency of statement.
Schematic representation of what respondents drew upon when
describing a serious experience. One respondent described the term
serious using an example that did not relate to a personal experience.
The bottom box represents characteristics of descriptions given within
the scope of personal experience
Fig. 2 Differences and
similarities: relevance of rare
adverse events to patient
concern. The thickness of the
line indicates the frequency of
the statement
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Patient 17: ‘‘One time, you know, that is rare.’’
Rare was described in terms of absolute occurrence, thus
disregarding considerations of the occurrence of an event
in relation to a population.
3.4 Concern for Future Rare, Serious Events
In general, participants were concerned about a gradual
worsening of their health, but not with new types of AEs. If
concerned about AEs, the concern was based on previous
experience of the respondents, and only events considered
serious were the cause of concern for future AEs. Presented
information about events that had not been experienced did
not give rise to concern. Participants had different strate-
gies to cope with concern for serious events.
Seriousness, described as limitations to everyday life or
recent frightening events, was a requirement for an expe-
rience to cause future concern.
Patient 18 illustrated how concerns for future serious,
rare events were considered in the scope of current expe-
rience. Earlier in the interview, Patient 18 had described
both heart and lung complications.
Interviewer: If this list had presented heart issues –
would that have caused concern for you?
P18: Yes.
Interviewer: If this list had presented respiratory
issues – would that have caused concern for you?
P18: Yes, it would – because I’m both a heart patient
and a lung patient.
Interviewer: If it had also been very rare – 1 in
10.000?
P18: Yes – I would have to consider it. I would,
because I have enough issues with my current con-
ditions. So, you do not want to add to that, right? Not
if you can avoid it.
The events that were the focus of concern for partici-
pants varied greatly but were related to prior adverse
experiences. Patient 03 illustrated this finding when she
was asked what type of AEs would make her reconsider a
medicinal treatment:
P03: ‘‘That could be a very small adverse event, like
headache. I have suffered from migraine in the past
and it is among the most horrible conditions.’’
In contrast to experienced serious events, which could
elicit concern, participants clearly indicated that informa-
tion alone did not cause concern (Fig. 3, lower left). Hence,
the AE table was generally read as a checklist that con-
firmed experienced events rather than a source of infor-
mation for future possible events.
P07: ‘‘I would only react to something I have
experienced.’’
P17: ‘‘Well, if I experienced new symptoms I would
definitely check with this paper. I would. Otherwise, I
wouldn’t.’’
Furthermore, when respondents read through the AE
tables, they focused on the less serious, prevalent events,
for example hypoglycemia, itching and constipation, rather
than seemingly more serious, rare events, such as ana-
phylactic reactions, renal failure, and neuropathy. Patient
05 illustrated this tendency:
Patient 05: ‘‘Well, there is no doubt that I would
always focus on the very common, the ones seen the
most, however common they are. I become less and
less interested the more we approach rare. I do not
belong in the very rare category.’’
Concerns were handled differently. Three approaches
were observed, all consciously or subconsciously neglect-
ing risks.
Respondents with close and positive relations with
their healthcare professionals (both nurses and doctors
were mentioned) deliberately placed confidence in the
ability of the professionals to assess the possibility for
future AEs.
Interviewer: ‘‘Do you lose interest when we discuss
the rare and very rare?’’
Patient 13: ‘‘No, no. It’s just that somebody else will
deal with this if it appears. I think that they have it
under control.’’
Fig. 3 Differences and similarities: patient concerns regarding future
adverse events in relation to previous experience. The thickness of the
line indicates the frequency of statement
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Similarly, these patients also trusted the healthcare
professionals to detect and act on AEs should they occur in
the future.
Another conscious approach was to acknowledge but
disregard the risk. These respondents considered future risk
as insignificant and hypothetical in comparison with their
experienced severely affected health.
Patient 03: ‘‘I couldn’t worry about something that
I’m not experiencing. It’s as simple as that. I’ve got
too much on my plate. Remember – I’ve got three
chronic diseases.’’
Since, the concern for future medicine-related AEs was
exceeded by the concern for present-day disease and
complications, respondents did not let a potential risk
affect their current concern.
Third, one respondent subconsciously neglected AEs of
drugs if they overlapped with known diabetic
complications.
Patient 12: I see retinopathy as a known problem in
relation to diabetes. Therefore, I don’t interpret this
information as if retinopathy is related to this
treatment.
When a potential AE caused by a medicine is instead
allocated to the disease progression, the perceived risk
related to the medicine is lowered. If interpreted as an
additional risk for an already likely complication, the
perceived risk related to the medicine would be increased.
4 Discussion
In summary, this study places personal serious adverse
experiences as a central factor impacting the perception of
risk and a driver for future concern in the context of health.
The results of this study also describe unexperienced
events as not evoking concern. Only respondents who
recalled an event that was considered as rare expressed
concern for future rare AEs. These associations are, for the
first time, proposed as relevant for patient involvement in
regulatory decisions.
Respondents had, if any, different definitions of the term
rare. The term serious was defined according to their own
experience, leading them to focus their concern on less
serious, more prevalent events instead of more serious, less
prevalent events.
Respondents had very different concerns, and had these
formative previous experiences not been first described by
the patients and connected by the analysis of this study,
their concerns would have seemed completely unrelated.
It was found that past personal experiences were the
main determinant of risk perception. However, not all
respondents with previous adverse experiences reported
increased levels of concern. These respondents had out-
sourced or projected their concerns to healthcare profes-
sionals. This observation mitigates the apparent difference
between respondents reporting concern and a lack of con-
cern for future AEs.
The Social Amplification of Risk Framework (SARF)
describes the process of individual risk assessment as
highly influenced by previous experiences [55]. This the-
oretical suggestion is aligned with the subset of respon-
dents described here who report heightened concerns about
AEs that overlap with previous experiences.
4.1 Future AEs
Respondents related the risk of future AEs to previously
experienced similar events. This complements prior
research by Knuth et al. where personal experiences with
an AE was shown to increase the perceived risk of that
event occurring again [56]. The findings are also in
accordance with the availability bias described by cog-
nitive bias theory, stating that ‘‘events that can be more
easily brought to mind or imagined are judged to be more
likely than events that could not easily be imagined’’
[23, 24].
Patients with no recalled adverse experiences largely
ignored the risk of a rare and serious event. Conversely, an
event recalled as frightening triggered the aversion of risk
factors for a similar event. The theory of probability
neglect [29, 57, 58] predicts that ‘‘Affect-rich outcomes
yield pronounced overweighting of small probabilities’’
[59]. In the present study, the concerns of the respondents
were focused on even minor events that could worsen their
present condition, rather than rare serious events.
4.2 Rare or Serious Events
Patients gave contradicting descriptions of the term ‘rare’.
One patient explained that his adverse experience was
listed in the AE table as rare but he did not feel the rarity
since he felt the effect every day. This underpins the binary
nature of an experience. From this perspective, an event is
either experienced or not, and, therefore, never considered
rare.
Another patient described thousands of repeated actions
(blood glucose measurements) as a reference for a rare
event (two cases of hypoglycemia). Under the regulatory
approach, one or multiple events experienced by the same
individual are counted as one occurrence [60]. However, in
the case of hypoglycemia, more than 10% of patients
treated with sugar-lowering medicine will experience the
event. This demonstrates an extreme difference between
respondents’ perception of hypoglycemia as rare, while
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health professionals consider hypoglycemia to be one of
the most prevalent AEs of antidiabetic treatment.
The framework of cognitive biases provides common
deviances from rationality. The alternative perspectives
regarding relevance of prevalence and the term rare pro-
posed by respondents do not fit a certain type of cognitive
bias and do not present as deviances from rationality.
Regarding serious events, there was a common theme in
the respondents’ descriptions. The term serious was mainly
related to previous personal experience and was often
related to the effects of such experiences on daily life. For
the patients interviewed, a recent life-changing event was
often considered to be more serious than a singular life-
threatening event that occurred a long time ago and that
had only a minor influence on daily life.
Respondents did not align with regulatory criteria for
seriousness. While the regulatory criteria all relate to the
consequences of an event [61], the observed patient criteria
also relate seriousness to perceived likelihood, to whether
the events have been experienced, and, if so, how far back
in time such an experience took place. The results confirm
and add detail to the existence of a certain mismatch in the
dimensions of risk assessment between patients and regu-
latory decision makers [62].
4.3 Participant Causality Assessment
From the interviews, it emerged that respondents linked AEs
to both disease progression (complications) and medicines
(side effects). The interviews detailed three underlying rea-
sons. First, a misunderstanding of terms such as complica-
tions, AE, and side effect was observed. Second, participants
revealed that they did not have the immediate impression of
being exposed to medicines-related AEs. Such relations
came to the respondents’ attention later and after probing as a
result of other relevant information given in the interview by
the respondent. Third, when the terminology was under-
stood, and events were remembered, it was still unclear for
respondents whether to link disease or medicine to an AE.
These are known problems inherent to the discipline of
causality assessment, the methodology of which was
described in the early 1980s by Naranjo et al [63]. The
divergences among respondents emphasize that elicitation
and categorization of adverse experiences could be influ-
enced by at least the observed factors. A recent study pro-
posed a methodology for self-assessment of adverse drug
reactions [64]. The authors also present literature on patient
causality assessment.
4.4 Strengths and Limitations
The inclusion criteria were selected to recruit patients with
experienced AEs to the study. These criteria ensured that
the interviews were not set in a hypothetical frame of risk
perceptions. However, this inclusion criterion did not
ensure that all participants had experienced a confirmed
medicine-related AE. Within the frame of the inclusion
criteria, it was sought to increase heterogeneity via the
described multiple recruitment routes. The resulting sample
is not heterogeneous regarding age, time since initial
diagnosis, and sex, but, despite this homogeny, respondents
were highly diverse in relation to perceptions of risk related
to rare serious AEs.
Self-perceived serious AEs permitted inclusion to this
study. However, during the interviews, two patients stated
that their experienced AEs were not considered serious.
These respondents confirmed the relevance of the inclusion
criteria by stating that questions on seriousness felt irrele-
vant due to their lack of experience.
The authors consider the following instances of bias rela-
ted to responder composition. Recruitment via local DDA
chapters tended to favor the participation of more commu-
nity-engaged patients. The community orientation of the
chairs of local DDA chapters indicated that events experi-
enced by patients that respondents felt some degree of
responsibility towards impacted risk perception in addition to
their personal experiences. Recruitment via diabetes clinics
was staff-mediated and favored the participation of those with
good relations to staff members, while recruitment via health
centers favored the participation of patients with curiosity
towards research, initiative, and enough confidence to
respond to the invitations distributed.
A majority of respondents were male. Although a more
balanced composition was desired, there was no indication that
prior experience was more or less formative of the risk per-
ceptionof eithermale or female participants.However,men are
reported to be more permissive of risk than females [65].
The age of 72 years (median) and time since diabetes
diagnosis of 16 years (median) indicate a group of partic-
ipants who have had a long time to consider health-related
risks. The findings of this study should be explored in a
broader spectrum of patients to investigate the degree of
impact from personal experience on risk perception.
A registry-based approach to recruitment could have been
feasible, but was considered disadvantageous due to a lack of
self-perceived seriousness criteria. The employment of a
multi-track parallel recruitment strategy increased diversity,
but not to a level where this sample could be considered
representative for patients with diabetes in Denmark.
Nonetheless, there was no indication among
respondents that risk perception was tied to the specific
disease. Had the focus of respondents been on the
development of complications through disease pro-
gression, or specifically related to a barrier for invasive
treatment, for example, this conclusion might have been
the opposite. The findings are therefore not considered
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to be restricted to patients with diabetes; however,
alignment to other disease groups should be investi-
gated specifically.
5 Conclusions
This study adds to the understanding of individual risk
perception by proposing that concern for future AEs is
driven by personal adverse experience. Events that were
either recalled as frightening or chronically impacted quality
of life were considered serious and, as such, qualified as a
driver for future concern. Therefore, patient experiences
should be investigated as a potentially pivotal stratification
variable when eliciting risk perceptions.
The authors propose that prior adverse experiences of
patients involved in regulatory decisions be documented
and presented, preferably with an indication of what events
were subjectively considered as serious. On this basis, the
authors advise that, when regulatory decision makers find it
relevant to qualify a decision with the input of patients, a
multitude of patients with representative adverse experi-
ences (including none) are included.
While this exploratory study identified prior experience
as a potentially important factor in risk perception in the
context of patient involvement, further research should
determine its extent and magnitude.
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